Preventive maintenance services for its Bruker Preclinical BioSpec 3T MRI System and Bruker Avance Neo 700 nuclear magnetic resonance (NMR) spectrometer
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Cancer Institute (NCI) intends to award a sole source purchase order to Bruker Biospin Corporation for preventive maintenance services for its Bruker Preclinical BioSpec 3T MRI System and Bruker Avance Neo 700 nuclear magnetic resonance (NMR) spectrometer located in Bethesda, MD. This is a Notice of Intent, not a request for quotations. Interested parties must submit a statement of capabilities within 7 days of publication if they believe they can meet the requirement.
Scope of Work
The contractor shall provide all labor, material, and equipment for preventive maintenance on the specified Bruker MRI and NMR systems. Services must be performed in accordance with the manufacturer's standard maintenance practices. These systems are critical for the Center for Clinical Cancer Metabolism's (CCM) collaborative research projects on metabolic 13C labeled tracer MRI and clinical/research metabolomics applications, requiring regular maintenance for consistent performance and to avoid damage or failure.
Contract & Timeline
- Type: Sole Source Purchase Order (FAR Subpart 13.106-1(b))
- Intended Awardee: Bruker Biospin Corporation
- Period of Performance: March 14, 2026, through March 13, 2028 (if all options exercised)
- NAICS Code: 811210 – Electronic and Precision Equipment Repair and Maintenance
- Size Standard: $34M
- Set-Aside: Not Applicable (Sole Source)
- Response Due: February 26, 2026 (7 days from publication)
- Published: February 19, 2026
Evaluation
NCI intends to solicit and negotiate directly with Bruker Biospin Corporation. Award is subject to approval of the Sole Source Justification. While this is not a request for competitive proposals, interested parties may submit a statement of capabilities with sufficient detail for the Government to determine if they can provide the requirement. Information received will be considered for determining whether to conduct a competitive procurement.
Additional Notes
This procurement will be processed using Simplified Acquisition Procedures. There is no solicitation package available. For questions, contact Elizabeth Bulger at elizabeth.bulger@hhs.gov.